Impact of gadopiclenol on decision making in patients with brain metastases

New gadolinium-based contrast agents (GBCAs) with high relaxivity could have an impact on decision making and treatment planning of brain metastases (BM). In this post-hoc analysis, patients with BM who underwent two separate magnetic resonance imaging (MRI) examinations, one with gadopiclenol and one with gadobenate dimeglumine, both at 0.1 mmol/kg, were included. This study showed that gadopiclenol at the dose of 0.1 mmol/kg improved detection and characterization of BM, and led to a change in treatment decisions in 2 of 13 patients.